-
Arch Biopartners to Expand LSALT Peptide Trial into the United States
Arch Biopartners is broadening the clinical trial footprint of its LSALT peptide into the US, a sign of growing momentum behind the investigational therapy. The expansion could accelerate patient enrollment and data collection.
-
New Clinical Trial Explores How Leucine Dosing Could Help Preserve Muscle During Fasting-Based Weight Loss
A newly registered study will examine whether different doses of the amino acid leucine can help young men maintain muscle mass while following a four-week alternate-day fasting program.
-
New Clinical Trial Aims to Improve Diabetes and Celiac Disease Screening for Underserved Communities
A newly launched study, ACCESS-T1D, seeks to improve early detection of Type 1 diabetes and celiac disease among underserved children and adults, expanding access to screening and care.
-
New Clinical Trial Explores BOTOX for Masseter Muscle Prominence
A new study is investigating whether BOTOX injections can safely and effectively reduce masseter muscle prominence, a common cosmetic concern related to lower facial width. The trial aims to expand treatment options for adults seeking a less invasive solution.
-
Pfizer’s Berobenatide Shows Promise in Phase IIb Trial
Pfizer has announced encouraging Phase IIb results for berobenatide, an investigational peptide therapy, marking another step forward in peptide-based treatment research.
-
GV1001 Peptide Shows Promise Against Alzheimer’s Disease in Mouse Study
A peptide derived from human telomerase, known as GV1001, has been shown in a new study to reverse signs of neurodegeneration in a mouse model of Alzheimer’s disease. The findings offer an encouraging new avenue for future therapeutic development.
-
Arch Biopartners Set to Expand LSALT Peptide Clinical Trial into the United States
Arch Biopartners is broadening its clinical trial program for its investigational LSALT peptide into the US, a sign of growing momentum behind the therapy’s development. The expansion could speed enrollment and bring the treatment closer to patients who may benefit.
-
GV1001 Peptide Shows Promise Against Neurodegeneration in Alzheimer’s Mouse Study
A peptide derived from human telomerase, GV1001, has been shown to rescue neurodegenerative changes in a mouse model of Alzheimer’s disease, offering a hopeful new direction for neuroprotective research.
-
FDA Advisory Panel Backs Expanded Access to Compounded Peptides
An FDA advisory panel has voted to add certain peptides to the agency’s approved list for pharmacy compounding, a move that could broaden patient access to these therapies through licensed compounding pharmacies.
-
FDA Panel Gives Nod to 6 Peptides, Signaling Path Forward for Access
An FDA advisory panel has voiced support for six peptide compounds, a step that could pave the way for expanded access and clearer regulatory standing for these popular compounds.